GuidelineBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2015
Indications for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation.
Guideline in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 160 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
160 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Real-World Issues and Potential Solutions in Hematopoietic Cell Transplantation during the COVID-19 Pandemic: Perspectives from the Worldwide Network for Blood and Marrow Transplantation and Center for International Blood and Marrow Transplant Research Health Services and International Studies Committee.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2020Guideline
- Haploidentical versus matched donor stem cell transplantation for patients with hematological malignancies: a systemic review and meta-analysis.Bone marrow transplantation · 2019Pooled it
- Trial
- Cryotherapy as prophylaxis against oral mucositis after high-dose melphalan and autologous stem cell transplantation for myeloma: a randomised, open-label, phase 3, non-inferiority trial.Bone marrow transplantation · 2019Trial
- An evidence-based stress management intervention for allogeneic hematopoietic stem cell transplant caregivers: development, feasibility and acceptability.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2017Trial
- JARID2 inhibition reprograms human hematopoietic progenitor cells to enhance bone marrow transplantation.Blood advances · 2026Article
- Long-term outcomes and GVHD in allogeneic hematopoietic cell transplantation abroad: a 14-year UAE multi-center cohort.BJC reports · 2026Article
- Longitudinal assessment and predictors of subjective taste change after hematopoietic cell transplantation (HCT).Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Pre-Transplant Prognostic Nutritional Index Independently Predicts Progression-Free Survival After Autologous Stem Cell Transplantation in Lymphoma.Journal of clinical medicine · 2026Article
- Outcomes of allogeneic hematopoietic cell transplantation in patients with carbapenem-resistant organisms infection: a propensity score-matched analysis.Frontiers in transplantation · 2026Article
- A Tacrolimus Population Pharmacokinetic Model for Adult Allogeneic Hematopoietic Cell Transplant Recipients Provides Clinical Opportunities for Precision Dosing.Clinical pharmacokinetics · 2025Article
- JARID2 Inhibition Reprograms Human Hematopoietic Progenitor Cells To Enhance Bone Marrow Transplantation.bioRxiv : the preprint server for biology · 2025Article
- Clonal Hematopoiesis and Outcomes After High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients with AML, Myeloma, and Lymphoma.International journal of molecular sciences · 2025Article
- Review
- Characteristics and outcomes of Bahraini pediatric patients sent abroad for bone marrow transplantation: A ten-year retrospective cohort study.World journal of transplantation · 2025Article
- Establishment of a machine learning-based prediction framework to assess trade-offs in decisions that affect post-HCT outcomes.Computers in biology and medicine · 2025Article
- Cellular sentinels: empowering survival and immune defense in hematopoietic stem cell transplantation through mesenchymal stem cells and T lymphocytes.BMC medicine · 2025Article
- Safety and long-term efficacy of autologous hematopoietic cell transplantation for patients with systemic sclerosis.Frontiers in medicine · 2025Article
- Dual-Double Stem Cell Ovarian Therapy: A Comprehensive Approach in Regenerative Medicine.International journal of molecular sciences · 2024Review
- Exploring facilitators and barriers to daily chlorhexidine gluconate bathing in adult patients undergoing hematopoietic stem cell transplantation.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Article
100 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Approximately 20,000 hematopoietic cell transplantation (HCT) procedures are performed in the United States annually. With advances in transplantation technology and supportive care practices, HCT has become safer, and patient survival continues to improve over time. Indications for HCT continue to evolve as research refines the role for HCT in established indications and identifies emerging indications where HCT may be beneficial. The American Society for Blood and Marrow Transplantation (ASBMT) established a multiple-stakeholder task force consisting of transplant experts, payer representatives, and a patient advocate to provide guidance on "routine" indications for HCT. This white paper presents the recommendations from the task force. Indications for HCT were categorized as follows: (1) Standard of care, where indication for HCT is well defined and supported by evidence; (2) Standard of care, clinical evidence available, where large clinical trials and observational studies are not available but HCT has been shown to be effective therapy; (3) Standard of care, rare indication, for rare diseases where HCT has demonstrated effectiveness but large clinical trials and observational studies are not feasible; (4) Developmental, for diseases where preclinical and/or early phase clinical studies show HCT to be a promising treatment option; and (5) Not generally recommended, where available evidence does not support the routine use of HCT. The ASBMT will periodically review these guidelines and will update them as new evidence becomes available.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.